Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(9):652-660; doi:10.1093/jnci/95.9.652
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Fueyo, J.
Right arrow Articles by Lang, F. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fueyo, J.
Right arrow Articles by Lang, F. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 9, 652-660, May 7, 2003
© 2003 Oxford University Press

ARTICLE

Preclinical Characterization of the Antiglioma Activity of a Tropism-Enhanced Adenovirus Targeted to the Retinoblastoma Pathway

Juan Fueyo, Ramon Alemany, Candelaria Gomez-Manzano, Gregory N. Fuller, Asadullah Khan, Charles A. Conrad, Ta-Jen Liu, Hong Jiang, Michael G. Lemoine, Kaori Suzuki, Raymond Sawaya, David T. Curiel, W. K. Alfred Yung, Frederick F. Lang

Affiliation of authors: J. Fueyo, C. Gomez-Manzano, G. N. Fuller, C. A. Conrad, T.-J. Liu, H. Jiang, M. G. Lemoine, R. Sawaya, W. K. A. Yung, F. F. Lang (Brain Tumor Center), A. Khan (Department of Pediatrics), University of Texas M. D. Anderson Cancer Center, Houston, TX; R. Alemany, Institut Català d’Oncologia, Barcelona, Spain; K. Suzuki, D. T. Curiel, Gene Therapy Center, University of Alabama at Birmingham.

Correspondence to: Juan Fueyo, M.D., Department of Neuro-Oncology, Box 316, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 (e-mail: jfueyo{at}mdanderson.org).

Background: Oncolytic adenoviruses are promising therapies for the treatment of gliomas. However, untargeted viral replication and the paucity of coxsackie-adenovirus receptors (CARs) on tumor cells are major stumbling blocks for adenovirus-based treatment. We studied the antiglioma activity of the tumor-selective Delta-24 adenovirus, which encompasses an early 1 A adenoviral (E1A) deletion in the retinoblastoma (Rb) protein-binding region, and of the Delta-24-RGD adenovirus. Delta-24-RGD has an RGD-4C peptide motif inserted into the adenoviral fiber, which allows the adenovirus to anchor directly to integrins. Methods: CAR and integrin expression were examined by flow cytometry in six glioma cell lines and in normal human astrocytes (NHAs). Adenoviral vectors containing green fluorescent protein (GFP) (AdGFP and AdGFP-RGD) were used to infect glioma cell lines with high or low CAR expression. Viability of glioma cells infected with different adenoviruses was assessed by trypan blue staining. Adenovirus replication was quantified with the infection-dose replication assay. Athymic mice carrying glioma xenografts received intratumoral injections of Delta-24-RGD or Delta-24 and were followed for survival, which was analyzed by the Kaplan–Meier method and the log-rank test. All statistical tests were two-sided. Results: Half the glioma cell lines expressed low levels of CAR (defined as <50% of cells expressing detectable CAR); all lines expressed integrins in more than 50% of cells. Infection of U-87 MG cells (a low-CAR-expressing line) with AdGFP-RGD resulted in approximately six times more GFP-positive cells than infection with AdGFP. Delta-24-RGD was more cytopathic to both low- and high-CAR-expressing glioma lines than Delta-24, and it replicated more efficiently in both cell lines. In the xenografted mice, intratumoral injection of Delta-24-RGD was associated with longer survival than intratumoral injection of Delta-24 (P<.001, log-rank test). Furthermore, 60% of Delta-24-RGD-treated mice but only 15% of Delta-24-treated mice survived more than 4 months (difference = 45%, 95% CI = 21% to 68%). Conclusions: The antitumor activity of Delta-24-RGD suggests that it has the potential to be an effective agent in the treatment of gliomas.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Acta Biochim Biophys SinHome page
W. Zhuang, Z. Qin, and Z. Liang
The role of autophagy in sensitizing malignant glioma cells to radiation therapy
Acta Biochim Biophys Sin, May 1, 2009; 41(5): 341 - 351.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
A. Nakamizo, T. Amano, W. Zhang, X.-Q. Zhang, L. Ramdas, T.-J. Liu, B. N. Bekele, T. Shono, T. Sasaki, W. F. Benedict, et al.
Phosphorylation of Thr18 and Ser20 of p53 in Ad-p53-induced apoptosis
Neuro-oncol, January 1, 2008; 10(3): 275 - 291.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. M. Alonso, C. Gomez-Manzano, B. N. Bekele, W.K. A. Yung, and J. Fueyo
Adenovirus-Based Strategies Overcome Temozolomide Resistance by Silencing the O6-Methylguanine-DNA Methyltransferase Promoter
Cancer Res., December 15, 2007; 67(24): 11499 - 11504.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. L.M. Lamfers, S. Idema, L. Bosscher, S. Heukelom, S. Moeniralm, I. H. van der Meulen-Muileman, R. M. Overmeer, P. van der Valk, V. W. van Beusechem, W. R. Gerritsen, et al.
Differential Effects of Combined Ad5-{Delta}24RGD and Radiation Therapy in In vitro versus In vivo Models of Malignant Glioma
Clin. Cancer Res., December 15, 2007; 13(24): 7451 - 7458.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Guse, T. Ranki, M. Ala-Opas, P. Bono, M. Sarkioja, M. Rajecki, A. Kanerva, T. Hakkarainen, and A. Hemminki
Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses
Mol. Cancer Ther., October 1, 2007; 6(10): 2728 - 2736.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H. Jiang, C. Gomez-Manzano, H. Aoki, M. M. Alonso, S. Kondo, F. McCormick, J. Xu, Y. Kondo, B. N. Bekele, H. Colman, et al.
Examination of the Therapeutic Potential of Delta-24-RGD in Brain Tumor Stem Cells: Role of Autophagic Cell Death
J Natl Cancer Inst, September 19, 2007; 99(18): 1410 - 1414.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. M. Alonso, M. Cascallo, C. Gomez-Manzano, H. Jiang, B. N. Bekele, A. Perez-Gimenez, F. F. Lang, Y. Piao, R. Alemany, and J. Fueyo
ICOVIR-5 Shows E2F1 Addiction and Potent Antiglioma Effect In vivo
Cancer Res., September 1, 2007; 67(17): 8255 - 8263.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
M. Candolfi, G. E. Pluhar, K. Kroeger, M. Puntel, J. Curtin, C. Barcia, A.K.M. G. Muhammad, W. Xiong, C. Liu, S. Mondkar, et al.
Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro
Neuro-oncol, July 1, 2007; 9(3): 245 - 258.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
O.-H. Lee, J. Xu, J. Fueyo, G. N. Fuller, K. D. Aldape, M. M. Alonso, Y. Piao, T.-J. Liu, F. F. Lang, B. N. Bekele, et al.
Expression of the Receptor Tyrosine Kinase Tie2 in Neoplastic Glial Cells Is Associated with Integrin {beta}1-Dependent Adhesion to the Extracellular Matrix
Mol. Cancer Res., December 1, 2006; 4(12): 915 - 926.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. ter Horst, S. M. Verwijnen, E. Brouwer, R. C. Hoeben, M. de Jong, B. H.C.G.M. de Leeuw, and P. A.E. Sillevis Smitt
Locoregional Delivery of Adenoviral Vectors
J. Nucl. Med., September 1, 2006; 47(9): 1483 - 1489.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Dong, L. Wang, J. J. Davis, W. Hu, L. Zhang, W. Guo, F. Teraishi, L. Ji, and B. Fang
Eliminating Established Tumor in nu/nu Nude Mice by a Tumor Necrosis Factor-{alpha}-Related Apoptosis-Inducing Ligand-Armed Oncolytic Adenovirus
Clin. Cancer Res., September 1, 2006; 12(17): 5224 - 5230.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
H. Ito, H. Aoki, F. Kuhnel, Y. Kondo, S. Kubicka, T. Wirth, E. Iwado, A. Iwamaru, K. Fujiwara, K. R. Hess, et al.
Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus.
J Natl Cancer Inst, May 3, 2006; 98(9): 625 - 636.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Gomez-Manzano, M. M. Alonso, W.K. A. Yung, F. McCormick, D. T. Curiel, F. F. Lang, H. Jiang, B. N. Bekele, X. Zhou, R. Alemany, et al.
Delta-24 Increases the Expression and Activity of Topoisomerase I and Enhances the Antiglioma Effect of Irinotecan
Clin. Cancer Res., January 15, 2006; 12(2): 556 - 562.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Kambara, H. Okano, E. A. Chiocca, and Y. Saeki
An Oncolytic HSV-1 Mutant Expressing ICP34.5 under Control of a Nestin Promoter Increases Survival of Animals even when Symptomatic from a Brain Tumor
Cancer Res., April 1, 2005; 65(7): 2832 - 2839.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Geoerger, G. Vassal, P. Opolon, C. M. F. Dirven, J. Morizet, L. Laudani, J. Grill, G. Giaccone, W. P. Vandertop, W. R. Gerritsen, et al.
Oncolytic Activity of p53-Expressing Conditionally Replicative Adenovirus Ad{Delta}24-p53 against Human Malignant Glioma
Cancer Res., August 15, 2004; 64(16): 5753 - 5759.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. L. Chu, D. E. Post, F. R. Khuri, and E. G. Van Meir
Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer
Clin. Cancer Res., August 15, 2004; 10(16): 5299 - 5312.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. Gomez-Manzano, W.K. A. Yung, R. Alemany, and J. Fueyo
Genetically modified adenoviruses against gliomas: From bench to bedside
Neurology, August 10, 2004; 63(3): 418 - 426.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.